Daniel Markowitz

Is there anything you are doing to the organization or the salesforce in order to prepare for this market unlock

Have these customers who received FDA Fast Track already placed orders for their Phase III clinical trials and you've already recognized revenues

it's impressive you're able to deliver on margins and EPS despite the customer timing in a very high-margin business

you mentioned promotional activity in Protein Sciences when talking about the margins there. Can you talk about these activities?

Is the plan to toggle the amount of ExoDx reinvestments depending on top line? Or would any upside to the organic top line lead to upside to margin expansion

Was that similar growth profile across the rest of the cell and gene portfolio?

Is it fair to assume that fiscal '26 margins at that 4Q exit rate of about 32% makes sense?

can you give some color on what the margins were in that business and help us understand the impact that divestiture

Assumed in the guide, it seems to imply a steep drop-off in the second half versus the first half.

called out NovaPure as a positive for the first time in a while. And backing up, I think mix shift is such an awesome part of the story

Can you talk about what you are hearing in customer conversations that suggest it could be a greater area of focus for customers going forward

you mentioned that demand outstripped supply.

I had a 2-parter for you. First, I'm curious on high-level headwinds and tailwinds to high-value components in 2026 as you see it today

I was curious if you could tell us the contribution in the quarter. I think it was 200 basis points in the first quarter

Can you discuss the potential upside you could continue to see from AnnexOne over coming quarters and years?